Health
Interleukin-6 inhibitors appear to be a more effective treatment for COVID-19 – News-Medical.Net
New research from Boston Medical Center found that patients experiencing severe COVID-19 symptoms had improved outcomes when administered an Interleukin-6 (IL6ri) inhibitor, sarilumab or tocilizumab, given to mediate severe systemic inflammatory responses.
New research from Boston Medical Center found that patients experiencing severe COVID-19 symptoms had improved outcomes when administered an Interleukin-6 (IL6ri) inhibitor, sarilumab or tocilizumab, given to mediate severe systemic inflammatory responses.
The treatment was more effective when administered earlier in the disease course and reduced mortality rates and the need for intubation. Published in the International Journal of Infectious Diseases, the results show Interleukin-6 inhibitors…
-
Business22 hours agoWhy is Alphabet stock worth less than Nvidia, Microsoft, Apple, and Amazon even though it is the most profitable S&P 500 company?
-
Noosa News18 hours agoTips to improve engagement – Proctor
-
Noosa News21 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
General16 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline